References

The Parkinson's-Reversing Breakthrough

Is There A Cure for Parkinson Disease

Get Instant Access

1. Nicoll RA. Introduction to the pharmacology of CNS. In: Katzung BG, ed. Basic and Clinical Pharmacology. Stanford: Appleton and Lange, 2000:351-363.

2. Hare ML. Tyramine oxidase. A new enzyme system in liver. Biochem J 1928; 22:968-979.

3. Pletscher A. The discovery of antidepressants: A winding path. Experientia 1991; 47:4-8.

4. Zeller EA, Barsky J. In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotinyl-2-isopropyl hydrazine. Proc Soc Exp Biol Med 1952; 81:459-461.

5. Loomer HP, Saunders JC, Kline NS. A clinical and pharamcodynamic evaluation of iproni-azid as a pyschic energizer. Psychiatry Res Rep Am Psychiatry Assoc 1957; 135(8):129-141.

6. Loomer HP, Saunders JC, Kline NS. Iproniazid, an amine oxidase inhibitor, as an example of a psychic energizer. Congres Rec 1957; 1382-1390.

7. Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Biochem Psychopharmacol 1972; 5:393-408.

8. Knoll H, Ecseri Z, Kelemen K, et al. Phenylisopropyl methylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn 1965; 155:154-164.

9. Yang HYT, Neff NH. The monoamine oxidases of brain: Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 1974; 189:733-740.

10. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17:1285-1297.

11. Pugh CEM, Quastel JH. Oxidation of aliphatic amines by brain and other tissues. Biochem J 1937; 31:2306-2321.

12. Quastel JH. Amine oxidases. In: Lajta A, ed. Handbook of Neurochemistry. New York: Plenum, 1970:285-312.

13. Davison AN. Physiological role of monoamine oxidase. Physiol Rev 1958; 38:729-747.

14. Lewinsohn R, Glover V, Sandler M. Development of benzylamine oxidase and MAO-A and -B in man. Biochem Pharmacol 1980; 29:1220-1230.

15. Riederer P, Reynolds GP, Yodim MBH. Selectivity of MAO inhibitors in human brain and their clinical consequences. In: Youdim MBH, Paykel ES, eds. Monoamine Oxidase Inhibitors—The State of the Art. Chichester: Wiley & Sons, 1981:63-76.

16. White HL, Tansik RL. Characterization of multiple substrate binding sites of MAO. In: Singer TP, von Korff RW, Murphy DL, eds. Monoamine Oxidase: Structure, Function, Altered Functions. New York: Academic Press, 1979:129-144.

17. Blaschko H. Amine oxidase and amine metabolism. Pharmacol Rev 1952; 4:415-458.

18. Reynolds GP, Riederer P, Rausch WD. Dopamine metabolism in human brain: effects of monoamine oxidase inhibition in vitro by (-)deprenyl and (+) and (-) tranylcypromine. J Neural Transm 1980; 16:173-178.

19. Fowler CJ, Callingham BA, Mantle TJ, et al. Monoamine oxidase A and B: a useful concept? Biochem Pharmacol 1978; 27:97-101.

20. Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 1982; 79:6385-6389.

21. Westlund KN, Kenney RM, Kochersperger LM, et al. Distinct monoamine oxidase A and B populations in primate brain. Science 1985; 230:181-183.

22. Oreland L. Monoamine oxidase, dopamine and Parkinson's disease. Acta Neurol Scand 1991; 84:60-65.

23. May T, Strauss S, Rommelspacher H. [3H] Harman labels selectively and with high affinity the active site of monoamine oxidase (EC1.4.3.4) subtype A (MAO-A) in rat, marmoset, and pig. J Neural Transm 1990; 32(suppl):93-102.

24. Nagy J, Salach JI. Identity of the active site flavin peptide fragments from the human "A"-form and the bovine "B"-form of monoamine oxidase. Arch Biochem Biophys 1981; 208:388-394.

25. Dahlstrom A, Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain-stem neurons. Acta Physiol Scand 1965; 62(suppl 232):1-55.

26. Marley E, Blackwell B. Interactions of monoamine oxidase inhibitors, amines, and foodstuffs. Adv Pharmacol Chemother 1970; 8:186-239.

Youdim MBH, Am OB, Yogev-Falach M, et al. Rasagiline: neurodegenerative, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 2005; 79: 172-179.

Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 1998; 9(4): 703-707.

Maruyama W, Akao Y, Youdim MBH, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear c\accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminer-gic neurotoxin, N-methyl(R)salsolinol. J Neurochem 2001; 78:727-735. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MBH, Naoi M. Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002; 24:675-682.

Sanz E, Romera M, Bellik L, Marco JI, Unzeta M. Indolalkylamines derivatives as antioix-idant and neuroprotective agents in an experiemental model of Parkinson's disease. Med Sci Monit 2004; 10(12):477-484.

Takahata K, Shimazu S, Katsuki H, Yoneda F, Akaike A. Effects of selegiline on antioxi-dant systems in the nigrostriatum in rat. J Neural Transm 2006; 113(2):151-158. Szende B, Bokonyi G, Bocsi J, Keri G, Timar F, Magyar K. Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites. J Neural Transm 2001; 108:25-33. Szende B, Magyar K, Szegedi Z. Apoptotic and antiapoptotic effect of (-)deprenyl and (-)-desmethyl-deprenyl on human cell lines. Neurobiology 2000; 8(3-4):249-255. Sharma SK, Carlson EC, Ebadi M. Neuroprotective actions of selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J Neurocytology 2003; 32:329-343.

Muralikrishnan D, Samantaray S, Mohanakumar KP. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity. Synapse 2003; 50:7-13.

Mizuta I, Ohta M, Ohta K, et al. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 2000; 279:751-755.

Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol 2004; 1987:455-459. Simon L, Szilagyi G, Bori Z, Orbay P, Nagy Z. (-)-D-Deprenyl attenuates apoptosis in experimental brain ischaemia. Eur J Pharmacology 2001; 430:235-241. Speiser Z, Mayk A, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm 1999; 106(7-8):593-606. Blandini F. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? CNS Drug Rev 2005; 11(2):183-194.

Abu-Raya S, Tabakman R, Blaugrund E, Trembovler V, Lazarovici P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacology 2002; 434:109-116. Am OB, Amit T, Youdim MBH. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004; 355:169-172.

Mandel S, Weinreb O, Amit T, Youdim MBH. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Rev 2005; 48:379-387. Carrillo MC, Minami C, Kitani K, et al. Enhancing effect of rasagiline on superoxide dis-mutase and catalase activities in the dopaminergic system in the rat. Life Sci 2000; 67(5):577-585.

Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of L-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol 1993; 243:241-247.

Riva MA, Molteni R, Racagni G. L-deprenyl potentiates cAMP-induced elevation of FGF-2 mRNA levels in rat cortical astrocytes. Neuroreport 1997; 8(9-10):2165-2168. Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MB. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 1999; 80:495-499.

49. Speiser Z, Katzir O, Rehavi M, Zabarski T, Cohen S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem Behav 1998; 60(2):387-393.

50. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 1999; 366(2-3):127-135.

51. Buys YM, Trope GE, Tatton WG. (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Crr Eye Res 1995; 14:119-126.

52. Hobbenaghi R, Tiraihi T. Neuroprotective Effect of Deprenyl in Sensory Neurons of Axo-tomized Dorsal Root Ganglion. Clin Neuropharmacol 2003; 26(5):263-269.

53. Tatton WG. Selegiline [(-)-deprenyl can mediate neuronal rescue rather than neuronal protection. Mov Disord 1993; 8:S20-S30.

54. Abu-Raya S, Blaugrund E, Trembovler V, Shilderman-Bloch E, Shohami E, Lazarovici P. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res 1999; 58(3):456-463.

55. Shahani N, Gourie-Devi M, Nalini A, et al. (-)-Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patients. ALS and Other Motor Neuron Disorders 20054; 5:172-179.

56. Kupsch A, Sautter J, Gotz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: Comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 2001; 108:985-1009.

57. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1984; 106:209-210.

58. Benakis A. Pharmacoketic study in man of 14 C jumex. Study report, data on file. Fra-mous Group Ltd Research Centre, 1981.

59. Szoko E, Kalasz H, Kerecsen L, et al. Binding of (-) deprenyl to serum proteins. Pol J Pharmacol Pharm 1984; 36:413-421.

60. Ahola R, Haapalinna A, Heinonen E, et al. Protection by L-deprenyl of intact peripheral sympathetic neurons exposed to neurotoxin 6-hydroxy-dopmaine (6-OHDA). New Trends Clin Neuropharamcol 1994; 7:287.

61. Fowler JS, MacGregor RR, Wolf AP, et al. Mapping human brain monoamine oxidase A and B with 11C labeled suicide inactivators and PET. Science 1987; 23:481-485.

62. Yoshida T, Yamada Y, Yamamoto T, et al. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 1986; 16:129-136.

63. Knoll J. R-(-)-deprenyl (selegiline, MoverganR) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm 1987; 25:45-66.

64. Heinonen EH, Lammintausta RAS. A review of the pharmacology of selegiline. Acta Neurol Scand 1991; 84:44-59.

65. Borbe HO, Neibich G, Nickel B. Kinetic evaluation of MAO-B activity following oral administration of selegiline and desmethyl-selegiline in rat. J Neural Transm 1990; 32:131-137.

66. Knoll J. The possible mechanism of action of (-)deprenyl in Parkinson's disease. J Neural Transm 1978; 43:177-193.

67. Bronzetti E, Felici L, Ferrante F, et al. Effect of ethylcholine mustard axiridium (AF64A) and of the monoamine oxidase-B-inhibitor L-deprenyl on the morphology of rat hippocampus. Int J Tissue React 1992; 14:175-181.

68. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997; 48:1070-1077.

69. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet 1991; 337:246.

70. Parkinson Study Group. Effects of Tocopherol and Deprenyl on the progression of Disability in early Parkinson's disease. N Engl J Med 1993; 328:176-183.

71. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245:519-522.

72. Palhagen S, Heinonen EH, Hagglund J, et al. Selegeline delays the onset of disability in de novo parkinsonian patients. Neurology 1998; 5l:520-525.

Myllylä VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline in de novo parkinsonian patients: The Finnish study. Mov Disord 1993; 8(suppl 1):41-44.

Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996; 39:37-45. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996; 39:29-36. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002; 51:604-612.

Allain H, Cougnard J, Neukirch HC. Selgiline in de novo parkinsonian patients: The French Selegiline Multicenter Trial. Acta Neurol Scand Suppl 1991; 136:73-78. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease. Ann Neurol 1995; 38:771-777. Sivertsen B, Dupont E, Mikkelsen B, et al. Selegiline and levodopa in early or moderately advanced Parkinson's disease: A double-blind controlled short and long-term study. Acta Neurol Scand 1989; 126:147-152.

Heinonen EH, Rinne UK. Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand 1989; 126:103-111.

Lees AJ. Current controversies in the use of selegiline hydrochloride. J Neural Transm 1987; 25:157-162.

Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988; 11:45-55. Palhagen S, Heinonen E, Hagglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006; 66:1200-1206.

Lees AJ, Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegi-line in patients with early mild Parkinson's disease. BMJ 1995; 311:1602-1607. Olanow CW, Fahn S, Langston JW, et al. Selegiline and mortality: A point of view. Ann Neurol 1996; 40:841-845.

Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998; 43:318-325.

Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A et al. Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort. Neurology 2005; 64:87-93.

Seager H. Drug-delivery products and the Zydis fast-dissolving dosage Form. J Pharm Pharmacol 1998; 50:375-382.

Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003; 110:1241-1255. Clarke A, Johnson ES, Mallard N, et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm 2003; 110:1257-1271.

Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM, Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19(4):426-432. Ondo WG. Pooled analysis of two identical phase 3 studies of a novel selegiline preparation as adjunctive therapy for Parkinson's disease. Mov Disord 2006; 21(suppl 13):S126.

Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and phar-macokinetics of rasagiline: a potent, selective and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 2004; 24(10):1295-1305.

Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. Arch Neurol 2002; 59:1937-1943.

Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61:561-566.

Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. Arch Neurol 2005; 62:241-248.

97. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365:947-954.

98. Giladi N, Rascol O, Brooks DJ, et al. Rasagiline treatment can improve freezing of gait in advanced Parkinson's disease: A prospective randomized, double blind, placebo and entacapone controlled study. Neurology 2004; 62(suppl 5):A329-A330.

99. Parkinson Study Group. Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson's disease (the TEMPO study). Neurology 2001; 56(suppl 3):A345.

100. Goetz C, Schwid SR, Eberly SW, Oakes D, Shoulson I, Parkinson Study Group TEMPO and PRESTO Investigators. Safety of rasagiline in elderly patients with Parkinson disease. Neurology 2006; 66(9):1427-1429.

Was this article helpful?

0 0

Post a comment